ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL

被引：0
|
作者：
Seo, B. [1 ]
Lee, S. [1 ]
Lee, I. [1 ]
Kim, S. [1 ]
Chiang, J. [1 ]
机构：
[1] Cipherome, San Jose, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-022
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [41] Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype
    Kagami, Takuma
    Yamade, Mihoko
    Suzuki, Takahiro
    Uotani, Takahiro
    Hamaya, Yasushi
    Iwaizumi, Moriya
    Osawa, Satoshi
    Sugimoto, Ken
    Umemura, Kazuo
    Miyajima, Hiroaki
    Furuta, Takahisa
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 906 - 913
  • [42] Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response
    Nastasi-Catanese, J. A.
    Padilla-Gutierrez, J. R.
    Valle, Y.
    Ortega-Gutierrez, F.
    Gallegos-Arreola, M. P.
    Figuera, L. E.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (04) : 4413 - 4421
  • [43] Study on the effect of CYP2C19 genetic polymorphism and plasma concentration on clopidogrel resistance
    Wu, Hui
    Chen, Xinli
    Ding, Yongli
    Deng, Yanglin
    Ma, Ruilan
    Chen, Xinyuan
    Li, Xuesong
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (05) : 1685 - 1691
  • [44] CYP2C19 GENETIC POLYMORPHISM ON CLOPIDOGREL RESPONSE IN VIETNAMESE PATIENTS WITH CORONARY STENTING
    Kim, N. T.
    Nguyen, M. N. T.
    Do, D. L.
    Nguyen, Q. H.
    Nguyen, T. T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E83 - E84
  • [45] Effects of CYP2C19 Variants on Platelet Reactivity in Acute Stroke Patients Treated with Clopidogrel
    Lei, Qi
    Yang, Qian
    Wang, Qian
    Yang, Jiangcun
    Lv, Jianmeng
    Guo, Xiaomin
    Kang, Bei
    ANNALS OF NEUROLOGY, 2015, 78 : S28 - S28
  • [46] Genetic variation in CYP2C19 affects exposure to the active metabolite and P2Y12 inhibition for clopidogrel but not prasugrel in patients with atherosclerosis
    Varenhorst, C.
    James, S.
    Erlinge, D.
    Braun, O. O.
    Winters, K. J.
    Man, M.
    Siegbahn, A.
    Walker, J.
    Wallentin, L.
    Close, S. L.
    EUROPEAN HEART JOURNAL, 2008, 29 : 327 - 327
  • [47] CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS
    Claassens, Daniel
    Bergmeijer, Thomas
    Vos, Gerrit J. A.
    Hermanides, Rik S.
    Hof, Arnoud
    van der Harst, Pim
    Barbato, Emanuele
    Morisco, Carmine
    Gin, Richard M. Tjon Joe
    Asselbergs, Folkert
    Mosterd, Arend
    Herrman, Jean-Paul
    Dewilde, Willem J. M.
    Deneer, Vera H. M.
    Ten Berg, Jurrien M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 76 - 76
  • [48] Genetic polymorphisms of CYP2C19 and effect of CYP2C19☆2 allele on clopidogrel P2Y12 inhibition in healthy Malaysian volunteers
    Sani, Y. N.
    Lim, S. C.
    Lim, L. H.
    Edwin, N. E. Y.
    Khan, N. Abdul Karim
    Goh, T. H.
    Serebruany, V. L.
    Yuen, K. H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 874 - 874
  • [49] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
  • [50] Mechanistic insights into the CYP2C19 genetic variants prevalent in the Indian population
    Naushad, Shaik Mohammad
    Vattam, Kiran Kumar
    Devi, Yadamreddy Kanaka Durga
    Hussain, Tajamul
    Alrokayan, Salman
    Kutala, Vijay Kumar
    GENE, 2021, 784
12345